Bristol Myers Squibb Co. stock rises Monday, still underperforms market
Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.
Why Did Bristol-Myers Squibb Co (BMY) Stock See 4.37% Surge in the Last 90 Days?
Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $56.57 which represents a decrease of $-0.22 or -0.39% from the prior close of $56.79. The stock opened at $56.34 and touched a low of $56.
Bristol-Myers Squibb Target of Unusually Large Options Trading (NYSE:BMY)
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was the target of some unusual options trading on Thursday. Investors purchased 296,826 call options on the stock. This represents an increase of 866% compared to the typical volume of 30,
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
Bristol Myers Squibb (BMY) closed the most recent trading day at $56.59, moving -0.35% from the previous trading session.
Bristol Myers Squibb call volume above normal and directionally bullish
Bullish option flow detected in Bristol Myers ( BMY) Squibb with 203,938 calls trading, 22x expected, and implied vol increasing over 5 points to 22.90%. Jan-25 52.5 calls and Jan-25 50 calls are the most active options, with total volume in those strikes near 108,400 contracts. The Put/Call Ratio is 0.02. Earnings are expected on February 6th.
Bristol-Myers Squibb Sees Unusually High Options Volume (NYSE:BMY)
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was the target of unusually large options trading activity on Thursday. Stock investors acquired 296,826 call options on the company. This is an increase of 866% compared to the typical volume of 30,
Bristol Myers Squibb Co. stock rises Friday, still underperforms market
The stock's fall snapped a two-day winning streak.
Jefferies Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY)
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report), with a price
Hosted on MSN3h
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?
Shares of Exelixis, Inc. EXEL have surged 50% in a year against the industry’s decline of 16.1%. The stock has also ...
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval
Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...
news.stocktradersdaily5d
When (BMY) Moves Investors should Listen
Short BMY slightly under 59.95, target 53.71, stop loss @ 60.12 Check the time stamp on this data. Updated AI-Generated ...
Final Trade: XLE, PANW, XHB, BMY
The final trades of the day with CNBC’s Melissa Lee and the Fast Money traders. The first migrant caravan of the year has set ...
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
PRINCETON, N.J., January 03, 2025 -- ( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43 rd Annual Healthcare Conference on Monday, ...
2 High-Yield Dividend Stocks to Buy Early in 2025
This strong market position generates substantial cash flows that support shareholder returns. Turning to the specifics, the ...
Halozyme: Recent Approvals Alter My Appetite
Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's ...